Back to Stocks

OSUR

ORASURE TECHNOLOGIES INC
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

OraSure Technologies is executing a high-conviction strategic pivot, deliberately shedding commoditized legacy revenue to build a leaner, innovation-driven diagnostic platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of a strategic pivot struggles to mask a troubling financial trajectory characterized by eroding core franchises and accelerating losses. Net revenues fell 7% year-over-year, with significant declines in HCV and the near-total disappearance of COVID-19 diagnostics.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every OSUR filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. OraSure is attempting to trade volume for value, sacrificing short-term top-line growth to purge low-margin legacy products in favor of a specialized diagnostic portfolio. The financial results are mixed: gross margins are trending upward, but operating losses are deepening as the company spends heavily on clinical trials and workforce realignment. The ultimate trajectory of the stock depends on the successful commercialization of its pipeline and the integration of the BioMedomics acquisition. While the $177 million cash reserve provides a significant safety net, the widening gap between R&D spending and current revenue generation creates a race against time. Investors are essentially weighing the probability of FDA clearances against the reality of a shrinking legacy business.

Selected Quarter

Core Takeaway

OraSure is purging low-margin revenue streams to focus on a high-margin pipeline, but widening losses and pending FDA approvals create a high-risk, high-reward scenario.

Investor Lens

The trade-off is between current cash burn and the potential for massive upside if the CT/NG and Colli-Pee FDA submissions are cleared.

Watch Next

FDA 510(k) clearance decisions for the rapid molecular self-test for CT/NG and the Colli-Pee at-home collection device.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.07Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%
bearishMay 8

Net revenues decreased 7% YoY and operating losses widened to $23.3 million.

earnings miss
70%
bullishMay 8

Gross profit margin increased to 42.3% from 41.1%.

margin expansion
40%
bullishMay 8

Spent $5 million on share repurchases during the quarter.

buyback
50%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. OraSure is attempting to trade volume for value, sacrificing short-term top-line growth to purge low-margin legacy products in favor of a specialized diagnostic portfolio. The financial results are mixed: gross margins are trending upward, but operating losses are deepening as the company spends heavily on clinical trials and workforce realignment. The ultimate trajectory of the stock depends on the successful commercialization of its pipeline and the integration of the BioMedomics acquisition. While the $177 million cash reserve provides a significant safety net, the widening gap between R&D spending and current revenue generation creates a race against time. Investors are essentially weighing the probability of FDA clearances against the reality of a shrinking legacy business.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.